Poster Session A
February 12, 2016
12:30 p.m.–3:30 p.m.
Elite Hall A


A02 A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers. Erin George, University of Pennsylvania, Philadelphia, PA, United States.

A03 Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research. Nora Navone, MD Anderson Cancer Center, Houston, TX, United States.

A04 Combined anti–MET/EGFR treatment results in complete tumor regression and prevents resistance onset in a MET-amplified gastrointestinal xenopatient cohort. Silvia Giordano, Fondazione Piemontese per la Ricerca sul Cancro-ONLUS - University of Torino, Candiolo, Torino, Italy.

A05 Developing patient derived xenograft (PDX) models for metastatic castration resistant prostate cancer (CRPC) during CYP17 inhibitor therapy. Fang Xie, Mayo Clinic, Rochester, MN, United States.


A07 Molecular characterization of patient-derived xenograft models of pediatric brain tumors. Sebastian Brabetz, German Cancer Research Center (DKFZ), Heidelberg, Germany.

A08 Neurosphere culture captures the clinical and molecular diversity of glioblastoma tumors. Ana deCarvalho, Henry Ford Hospital, Detroit, MI, United States.


A10 Plerixafor inhibits myeloid cell recruitment and improves the radioresponse in patient-derived cervix cancer xenograft models. Naz Chaudary, Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, Ontario, Canada.

A11 Using a patient-derived orthotopic xenograft (PDOX) model to screen drugs targeting renal cell carcinoma (RCC) metastasis—A personalized therapeutic strategy. Li Li, Ochsner Clinic Foundation, New Orleans, LA, United States.

A12 Developing PDeX (patient derived explant) to determine the basis for response to AR-directed therapeutics. Ayesha Shafi, Thomas Jefferson University, Philadelphia, PA, United States.

A13 Development of a drug response assessment platform for biopsy-derived tumor models. David Kodack, Massachusetts General Hospital, Boston, MA, United States.


A16 Establishment and characterization of CCGL007, a novel human chronic lymphocytic leukemia cell line. Ching-Chuan Kuo, National Health Research Institutes, Zhunan, Taiwan.


A18 High content 3D image analysis of patient-derived organoids. Erin Spiller, University of Southern California, Los Angeles, CA, United States.


A20 Personalized models to guide precision medicine. Chantal Pauli, Institute for Precision Medicine, WCM, New York, NY, United States.

A21 Accurate molecular fidelity of patient-derived xenograft (PDX) models to original human tumors and to The Cancer Genome Atlas (TCGA). Jennifer Jaskowiak, Champions Oncology, Hackensack, NJ, United States.

A22 Breast cancer patient-derived xenograft (PDX) models developed in “humanized” mice. Roberto Rosato, Houston Methodist Cancer Center, Houston, TX, United States.

A23, PR03 Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC. Anna Capasso, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A24 Early-stage pancreatic cancer patient derived xenograft (PDX) models established from endoscopic ultrasound (EUS) fine needle aspiration (FNA) biopsies. Kerrington Smith, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States.


A27 Addiction to the NF-κB-triggered IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells. Noriko Gotoh, Cancer Research Institute, Kanazawa University, Kanazawa City, Japan.

A28 Challenging new epigenetic vulnerabilities in human metastatic melanoma PDXs. Luisa Lanfrancone, European Institute of Oncology, Milano, Italy.

A29 Evaluating the dynamics of epigenetic changes conferring targeted cancer drugs resistance in tumor xenograft propagation model. REN-IN YOU, Tzu Chi University, Hualien, Taiwan.

A30 Modeling an immunotherapy of NK mechanism on a NSCLC patient derived xenograft. Henry Li, Crown Bioscience, Santa Clara, CA, United States.


A33 The implication of patient derived tumor cell (PDTC) tested/screened with novel microtube array membrane (MTAM)-based hollow fiber assay (HFA). Chien-Chung Chen, Taipei Medical University, Taipei, Taiwan.

A34 A comprehensive panel of patient-derived orthotopic xenograft mouse models of malignant brain tumors. Lin Qi, Texas Children’s Cancer Center; Departments of Pediatrics, Baylor College of Medicine, Houston, TX, United States.


A37 Dual wavelength near-infrared fluorescence imaging of VEGF-A and IGF-1R in ovarian cancer patient-derived xenografts. Steven De Jong, University Medical Center Groningen, Groningen, Netherlands.


A39 Patient-derived xenografts to test emerging therapies for triple negative breast cancer. Kurt Evans, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A41 Use of patient-derived tumor xenografts (PDX) for discovery and development of an anti-Notch2/3 monoclonal antibody targeting cancer stem cells. Marcus Fischer, OncoMed Pharmaceuticals, Redwood City, CA, United States.

A42 Using a PDX tumor bank to screen for cancer stem cell therapies. James Evans, OncoMed Pharmaceuticals, Redwood City, CA, United States.
**Poster Session B**
February 13, 2016
4:45 p.m.–7:15 p.m.
*Elite Hall A*

**B01** Autopsy derived orthotopic xenograft (ADOX) mouse models for terminal pediatric brain tumors. Lin Qi, Laboratory of Molecular Neuro-oncology, Texas Children’s Cancer Center, Houston, TX, United States.

**B02** Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers. Violeta Serra, Vall d’Hebron Institute of Oncology, Barcelona, Spain.

**B03** Dissecting molecular pathways in human tumor vs. mouse stromal environment in patient-derived cancer models. Emily Park, Advanced Cell Diagnostics, Inc., Hayward, CA, United States.

**B04** Identification of molecular predictors of differential chemotherapy response using patient-derived xenografts. Michael Lewis, Baylor College of Medicine, Houston, TX, United States.

**B05** Patient-derived GBM tumors versus patient-derived primary cells and GBM cell lines: Lessons from microRNA profiling. Paula Ofek, Tel Aviv University, Tel Aviv, Israel.

**B06** Studying cytarabine resistance through PDX models in acute myeloid leukemia. Thomas FARGE, INSERM, Toulouse, France.

**B07** Screening of patient-derived carcinoma cells and animal models identifies transcription as target in pancreatic cancer. Vladimir Khazak, NexusPharma Inc., Philadelphia, PA, United States.

**B08** Patient-derived xenografts of oral squamous cell carcinoma: A model system for the identification of prognostic molecular signatures and for preclinical assessment of targeted therapies. Laurie Ailles, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

**B09** Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: Clinically relevant models for research and personalized medicine. Laurie Ailles, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

**B10, PR01** Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids. Senthil Muthuswamy, Beth Israel Deaconess Medical Centre/Harvard Medical School, Boston, MA, United States.

**B11** Epigenetic therapy to target neuroendocrine prostate cancer using precision medicine models. Loredana PUCA, Weill Cornell Medicine, New York, NY, United States.

**B12** Establishment of paired primary neurosphere and monolayer cells of mouse xenograft derived from pediatric brain tumors. Yuchen Du, Baylor College of Medicine, Houston, TX, United States.

**B13** Human pancreatic cancer organoids for functional dependency profiling. Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, MA, United States.
B14, PR04 Integration of CRISPR-Cas9, RNAi and pharmacologic screens identify actionable targets in a rare cancer. Andrew Hong, Dana-Farber Cancer Institute, Boston, MA, United States.

B15 Patient-derived pancreatic adenocarcinoma cells: A new model system to define chemotherapy resistance mechanisms and to improve targeted personalized treatment. Erika Parasido, Georgetown University, Washington, DC, United States.


B18 B-cell lymphoma patient-derived xenograft models: The road to personalized therapy. Leo Zhang, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B19 Breast cancer patient-derived xenografts: The University of Illinois at Chicago Cancer Center experience. Huiping Zhao, University of Illinois at Chicago, Chicago, IL, United States.

B20 Development of metastatic patient-derived xenografts (PDXs) for accurate assessment of anti-metastatic therapeutics in pre-clinical settings. Elena Pugacheva, WVU Cancer Institute, Morgantown, West Virginia, United States.


B22 Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer. Li Liang, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.


B24 Patient-derived tumor xenograft to study cancer stem cells is pediatric sarcomas. Nino Rainusso, Baylor College of Medicine, Houston, TX, United States.

B25 The critical importance of the blood-brain barrier in modulating the response to otherwise highly effective targeted therapies in patient-derived orthotopic glioblastoma xenografts. Jann Sarkaria, Mayo Clinic, Rochester, MN, United States.


B27, PR06 Conditional reprogramming is successful in generating patient-derived stable cell cultures from rare aggressive tumors. Seema Agarwal, Georgetown University Medical Center, Washington, DC, United States.
B28 Development of next-generation breast cancer PDX models by applying intra mammary fat pad and intraductal tumor transfer. Lena Vockentanz, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.


B30 Establishment and maintenance of a PDX Core Facility. Marissa Mattar, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B31 Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile duct carcinomas. Nikolina Radulovich, University Health Network, Toronto, Ontario, Canada.

B32 Fidelity of genomic and proteomic features of patient-derived xenografts of lung cancers. Nhu-An Pham, University Health Network, Toronto, Ontario, Canada.


B34 Integrated approaches to treating lung adenocarcinoma resistant to targeted therapy. Jin Jen, Mayo Clinic, Rochester, MN, United States.

B35 Strategies to build a health disparity PDX model of human lung cancer. Brid Ryan, National Cancer Institute, Bethesda, MD, United States.

B36 Summary of 50 cases of patient-derived colorectal cancer xenografts; Problems and tips to obtain appropriate results in translational researches. Hisatsugu Maekawa, Kyoto University, Kyoto, Japan.

B37 Chemi-genomic analysis of patient-derived xenografts to identify personalized therapies for medulloblastoma. Jessica Rusert, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

B38 Clinical applications of PDX/NOG models for personalized chemotherapy—Possible use in chemo-sensitivity testing and clinical sequencing. TSUYOSHI CHIJIWA, Central Institute for Experimental Animals, Kawasaki, Japan.

B39 Identification and targeting mediators of chemoresistance using the patient-derived xenograft model of ovarian cancer. Charles Landen, University of Virginia, Charlottesville, VA, United States.

B40 Mouse clinical trials: integrating PDX models of sarcoma subtypes with genomics to replicate patient responses to cancer therapeutics. Angela Davies, Champions Oncology, Hackensack, NJ, United States.
Poster Session B
February 13, 2016
4:45 p.m.–7:15 p.m.
Elite Hall A

B41 Pan-RAF dimerization inhibitor-sensitive BRAF<sup>V600E</sup> kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Kristel Kemper, The Netherlands Cancer Institute, Amsterdam, Netherlands.


B43 PILOT: A patient-oriented in vivo functional platform to identify new lethalities and optimize cancer treatment. Alessandro Carugo, MD Anderson Cancer Center, Houston, TX, United States.

B44 When murine tumors are thought to be human: A drawback of patient derived xenografts. Camino Menéndez, CNIO, Madrid, Spain.

B45 Huntsman Cancer Institute Preclinical Research Resource (PRR) Core. David Lum, Huntsman Cancer Institute, Salt Lake City, UT, United States.

B46 Inhibition of STAT3 enhances the radiosensitizing effect of Temozolomide in vitro and in vivo: Validation using patient-derived glioblastoma model. In Ah Kim, Seoul National University, Seoul, Korea, Republic Of.